NCT04300504

Brief Summary

Growing evidence suggests that dynapenic abdominal obesity is associated with a greater risk of falls, functional disability and hospitalisation compared to those with dynapenia, obesity or neither phenotype. Understanding the pathogenesis underlying this phenotype has the potential to inform potential treatment strategies. MicroRNAs can act as messengers at the cellular level to promote or block processes for muscle growth and repair, amongst other things. There is evidence that ageing changes microRNA levels in the muscle and that these changes may result in reduced muscle quality and quantity. However, it is not known whether being obese can change microRNA levels in muscle and how this relates to physical performance. The aim of this study is to investigate the effect of dynapenic abdominal obesity on microRNA levels in serum and muscle quality and quantity in the legs of older women. This is an observational, cross-sectional study. The investigators will recruit 4 groups of older women: normal weight, normal weight with dynapenia, obese and obese with dynapenia. The investigators will measure the microRNA levels in serum. The investigators will measure the quantity and fat content of muscle in the legs using magnetic resonance imaging. Muscle strength, fatigue and balance will be measured using gait (walking) analysis, balance tests, and a machine designed to measure leg strength and fatigue. The investigators will measure and compare microRNA levels between groups. The investigators will use databases and computer programmes to look at all of the microRNAs which are different between groups and see how they affect the muscle. The investigators will compare muscle strength, size and fatigue between groups. The investigators will explore relationships of muscle quantity and quality measures with microRNA changes in the muscle. This approach will allow the investigators to understand how obesity affects the microRNA profile of muscle and whether this translates into impairment of function and mobility.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 19, 2019

Completed
3 months until next milestone

First Posted

Study publicly available on registry

March 9, 2020

Completed
1.5 years until next milestone

Study Start

First participant enrolled

September 1, 2021

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 17, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 17, 2023

Completed
Last Updated

November 18, 2023

Status Verified

November 1, 2023

Enrollment Period

1.5 years

First QC Date

December 19, 2019

Last Update Submit

November 15, 2023

Conditions

Keywords

obesitysarcopeniadynapeniamicroRNA

Outcome Measures

Primary Outcomes (1)

  • Differential microRNA expression, expressed as fold-change and p-values, measured using real time quantitative polymerase chain reaction (RT-qPCR) between normal weight and obese groups, further stratified by dynapenia

    Serum analyses

    1 day (one measurement )

Secondary Outcomes (5)

  • mean difference in distance walked during 6 minute walk test between normal weight and obese, further stratified by dynapenia

    1 day (one measurement )

  • mean difference in muscle mass and volume measures between normal weight and obese, further stratified by dynapenia MRI

    1 day (one measurement )

  • mean difference in muscle mass and volume measures between normal weight and obese, further stratified by dynapenia DXA

    1 day (one measurement )

  • mean difference in muscle strength between normal weight and obese, further stratified by dynapenia

    1 day (one measurement )

  • mean difference in fatigue between normal weight and obese, further stratified by dynapenia

    1 day (one measurement )

Study Arms (4)

normal weight, not dynapenic

BMI 18.5 to 25kg/m2, waist circumference \<= 88cm, healthy women aged 60-80 years, time to complete 5 chair stands \<15 seconds

Other: observational study

normal weight, dynapenic

BMI 18.5 to 25kg/m2, waist circumference \<= 88cm,healthy women aged 60-80 years, time to complete 5 chair stands \>15 seconds

Other: observational study

obese, not dynapenic

BMI 30 to 40kg/m2, waist circumference \> 88cm, healthy women aged 60-80 years, time to complete 5 chair stands \<15 seconds

Other: observational study

obese, dynapenic

BMI 30 to 40kg/m2, waist circumference \> 88cm, women aged 60-80 years, time to complete 5 chair stands \>15 seconds

Other: observational study

Interventions

observational study

normal weight, dynapenicnormal weight, not dynapenicobese, dynapenicobese, not dynapenic

Eligibility Criteria

Age60 Years - 80 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Healthy Caucasian Women Recruited from around South Yorkshire and Merseyside, UK

You may qualify if:

  • Caucasian
  • Female
  • BMI 18.5-25 or 30-40kg/m2
  • Ages 60-80 years
  • Sufficiently mobile to undergo scanning and biomechanical testing
  • Able to remain motionless during scans
  • Able and willing to participate in the study and provide written informed consent

You may not qualify if:

  • BMI 18.5-25kg/m2 AND waist circumference \>88cm i.e. normal weight AND abdominally obese
  • BMI 30-40kg/m2 AND waist circumference \<88cm i.e. obese AND not abdominally obese
  • History of any long-term immobilisation (duration greater than 2 weeks in the past 12 months)
  • History of hospital admission in the past 3 months
  • History of recent significant weight loss (5% in 3 months or 10% in 6 months)
  • Diabetes mellitus
  • History of current conditions which may affect muscle metabolism
  • Malabsorption syndromes e.g. inflammatory bowel disease, pancreatic insufficiency etc.
  • Chronic renal disease
  • Diagnosed eating disorder
  • Conditions which prevent the undertaking or analysis of the MRI and DXA scans or the interpretation of their results e.g. hip prosthesis, metal implants etc.
  • Conditions which prevent the undertaking of the fatigue protocols e.g. hypertension etc.
  • Use of medications or treatment known to affect muscle metabolism
  • o Anabolic steroids, glucocorticoids, antiretrovirals etc.
  • Excessive alcohol intake defined as greater than 21 units per week
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Sheffield/Sheffield Teaching Hospitals

Sheffield, South Yorkshire, United Kingdom

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum

MeSH Terms

Conditions

ObesitySarcopenia

Interventions

Observation

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsMuscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, Anatomical

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Study Officials

  • Jennifer Walsh

    University of Sheffield

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 19, 2019

First Posted

March 9, 2020

Study Start

September 1, 2021

Primary Completion

March 17, 2023

Study Completion

March 17, 2023

Last Updated

November 18, 2023

Record last verified: 2023-11

Locations